B
AMPH icon

Bailard’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bailard’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,600
Closed -$322K – 703
2023
Q2 		$322K Sell
5,600
-800
-13% -$35.5K 0.01% 492
2023
Q1 		$240K Buy
+6,400
New +$210K 0.01% 580

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bailard's AMPH Position: Q3 2023 in Review

Bailard sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2023, closing a stake of 5,600 shares — an estimated $322K sold.

Bailard first reported a position in AMPH in Q1 2023 and held it in 2 quarters. The position peaked at $322K in Q2 2023. 255 funds tracked by Wall St. Rank hold AMPH as of Q3 2023.

  • Bailard reported no remaining Amphastar Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Bailard sold 5,600 Amphastar Pharmaceuticals shares in Q3 2023, an estimated $322K.
  • Bailard first reported a position in Amphastar Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Bailard's Amphastar Pharmaceuticals position peaked at $322K in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2023.

Based on Bailard's 13F filing for Q3 2023, filed 24 Oct 2023.